Rationale and design of theguide-it study: Guiding evidence based therapy usingbiomarker intensified treatment inheart failure

JACC: Heart Failure

Volumn 2, Issue 5, 2014, Pages 458-465

  Felker, G Michael ^a   Ahmad, Tariq ^a   Anstrom, Kevin J ^a   Adams, Kirkwood F ^b   Cooper, Lawton S ^c   Ezekowitz, Justin A ^d   Fiuzat, Mona ^a   Houston Miller, Nancy ^e   Januzzi, James L ^f   Leifer, Eric S ^c   Mark, Daniel B ^a   Desvigne Nickens, Patrice ^c   Paynter, Gayle ^a   Piña, Ileana L ^g   Whellan, David J ^h   O'Connor, Christopher M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e STANFORD UNIVERSITY   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g MONTEFIORE MEDICAL CENTER   (United States)

^h THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Biomarkers; Clinical trial; Heart failure

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST;

ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOLLOW UP; GUIDING EVIDENCE BASED THERAPY USING BIOMARKER INTENSIFIED TREATMENT IN HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PROGNOSIS; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC HEART FAILURE;

EID: 84908060979     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.05.007     Document Type: Article

References (45)

1. Schocken D.D., Benjamin E.J., Fonarow G.C., et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008, 117:2544-2565.
2. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JAm Coll Cardiol 2013, 62:e147-e239.
3. Lee D.S., Mamdani M.M., Austin P.C., et al. Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000. Am J Med 2004, 116:581-589.
4. Stafford R.S., Radley D.C. The underutilization of cardiac medications of proven benefit, 1990 to 2002. JAm Coll Cardiol 2003, 41:56-61.
5. Fiuzat M., Wojdyla D., Kitzman D., et al. Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. JAm Coll Cardiol 2012, 60:208-215.
6. Fonarow G.C., Yancy C.W., Albert N.M., et al. Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Circ Heart Fail 2008, 1:98-106.
7. Fonarow G.C., Albert N.M., Curtis A.B., et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation 2010, 122:585-596.
8. Desai A.S. Home monitoring heart failure care does not improve patient outcomes: looking beyond telephone-based disease management. Circulation 2012, 125:828-836.
9. Fuat A., Hungin A.P., Murphy J.J. Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. BMJ 2003, 326:196.
10. Cleland J.G., Louis A.A., Rigby A.S., Janssens U., Balk A.H. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care Management System (TEN-HMS) study. JAm Coll Cardiol 2005, 45:1654-1664.
11. Whellan D.J., Hasselblad V., Peterson E., O'Connor C.M., Schulman K.A. Metaanalysis and review of heart failure disease management randomized controlled clinical trials. Am Heart J 2005, 149:722-729.
12. Bourge R.C., Abraham W.T., Adamson P.B., et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. JAm Coll Cardiol 2008, 51:1073-1079.
13. Fonarow G.C. Heart failure disease management programs: not a class effect. Circulation 2004, 110:3506-3508.
14. Januzzi J.L., Sakhuja R., O'Donoghue M., et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 2006, 166:315-320.
15. Fonarow G.C., Peacock W.F., Phillips C.O., Givertz M.M., Lopatin M. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. JAm Coll Cardiol 2007, 49:1943-1950.
16. Cleland J.G., McMurray J.J., Kjekshus J., et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). JAm Coll Cardiol 2009, 54:1850-1859.
17. Anand I.S., Fisher L.D., Chiang Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003, 107:1278-1283.
18. McKelvie R.S., Yusuf S., Pericak D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study: the RESOLVD Pilot Study Investigators. Circulation 1999, 100:1056-1064.
19. Frantz R.P., Olson L.J., Grill D., et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. Am Heart J 2005, 149:541-547.
20. Tsutamoto T., Wada A., Maeda K., et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. JAm Coll Cardiol 2001, 37:1228-1233.
21. Fruhwald F.M., Fahrleitner-Pammer A., Berger R., et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J 2007, 28:1592-1597.
22. Masson S., Latini R., Anand I.S., et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). JAm Coll Cardiol 2008, 52:997-1003.
23. Eurlings L.W.M., van Pol P.E.J., Kok W.E., et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heartfailure IMprove heart fAilure morbidity and mortality?) study. JAm Coll Cardiol 2010, 56:2090-2100.
24. Shah M.R., Califf R.M., Nohria A., et al. The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. JCard Fail 2011, 17:613-621.
25. Troughton R.W., Frampton C.W., Yandle T.G., Espiner E.A., Nicholls M.G., Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000, 355:1126-1130.
26. Lainchbury J.G., Troughton R.W., Strangman K.M., et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. JAm Coll Cardiol 2009, 55:53-60.
27. Pfisterer M., Buser P., Rickli H., et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009, 301:383-392.
28. Januzzi J.L., Rehman S.U., Mohammed A.A., et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. JAm Coll Cardiol 2011, 58:1881-1889.
29. Berger R., Moertl D., Peter S., et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure: a 3-arm, prospective, randomized pilot study. JAm Coll Cardiol 2010, 55:645-653.
30. Jourdain P., Jondeau G., Funck F., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. JAm Coll Cardiol 2007, 49:1733-1739.
31. Persson H., Erntell H., Eriksson B., Johansson G., Swedberg K., Dahlstrom U. Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure-SIGNAL-HF (Swedish Intervention study-Guidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail 2010, 12:1300-1308.
32. Felker G.M., Hasselblad V., Hernandez A.F., O'Connor C.M. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009, 158:422-430.
33. Januzzi J.L. The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use. Arch Cardiovasc Dis 2012, 105:40-50.
34. Masson S., Latini R., Anand I.S., et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006, 52:1528-1538.
35. Masson S, Latini R, Carbonieri E, etal. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 2010,12:338-47.
36. Hauck W.W., Anderson S., Marcus S.M. Should we adjust for covariates in nonlinear regression analyses of randomized trials?. Control Clin Trials 1998, 19:249-256.
37. Curtis L.H., Hammill B.G., Eisenstein E.L., Kramer J.M., Anstrom K.J. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 2007, 45:S103-S107.
38. Konstam M.A., Gheorghiade M., Burnett J.C., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007, 297:1319-1331.
39. Freidlin B., Korn E.L., Gray R. Ageneral inefficacy interim monitoring rule for randomized clinical trials. Clin Trials 2010, 7:197-208.
40. Haybittle J.L. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 1971, 44:793-797.
41. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976, 34:585-612.
42. Januzzi J.L., Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation 2013, 127:500-507. discussion 508.
43. Porapakkham P., Zimmet H., Billah B., Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 2010, 170:507-514.
44. Savarese G., Trimarco B., Dellegrottaglie S., et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PloS One 2013, 8:e58287.
45. Gaggin H.K., Truong Q.A., Rehman S.U., et al. Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. Congest Heart Fail 2013, 19:135-142.